Hospital Nuclear Medicine Radiology Radiopharmaceuticals 
AuntMinnie
APRIL 15, 2024
Total nuclear medicine patient study volumes decreased by 5.7% decrease in hospital-based studies and a 2.5% decrease in total procedures each year, with hospital-based procedures declining by 5.5% and non-hospital procedures increasing by 1.2%. and non-hospital procedures increasing by 1.2%. Of these, 5.8
AuntMinnie
JULY 12, 2024
As nuclear medicine therapies gain stature compared to nuclear medicine in diagnostic imaging, hospital administrators may be eyeing the potential of adding theranostics services. A shortage of nuclear medicine technologists means a theranostics center may need to limit its patient volume.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
AuntMinnie
MAY 8, 2024
Theranostics treatments are used with increasing frequency now since the approvals and expansions of Lutathera (lutetium-177 [Lu-177]) DOTATATE, a radiopharmaceutical for neuroendrocrine tumors (NETs) and Pluvicto, Lu-177 PSMA-617, for prostate cancer. In addition, dose calculations estimated mean dose to the arm of approximately 3 Gy.
AuntMinnie
MARCH 7, 2024
In terms of 2023 spending, the average radiopharmaceutical expenditure per fixed PET site is estimated to be $517,000. In 2023, 38% of PET systems were operated by the PET department, 28% by nuclear medicine, 24% by radiology/imaging, 5% by radiation oncology, and 2% by molecular imaging.
Imaging Technology
JUNE 11, 2024
She will also raise awareness of nuclear medicine’s value to clinical colleagues and patients and will be laser-focused on breaking down barriers to radiopharmaceutical availability, reimbursement, affordability, and funding. An active SNMMI member, Jacene has been involved in many aspects of the organization.
AuntMinnie
MARCH 26, 2024
Food and Drug Administration's (FDA) approvals of radiopharmaceuticals for neuroendocrine tumors and then for prostate cancer, theranostics has picked up momentum in clinical practice, propelled by encouraging research. Since 2013 we've had several more radiopharmaceutical therapies get FDA approval.
Imaging Technology
FEBRUARY 21, 2024
milla1cf Wed, 02/21/2024 - 18:58 February 21, 2024 — Blue Earth Therapeutics , a Bracco company and emerging leader in the development of innovative next generation therapeutic radiopharmaceuticals, is pleased to share the publication of promising early clinical data with 177Lu-rhPSMA-10.1 177Lu-rhPSMA-10.1
Expert insights. Personalized for you.
111 
Let's personalize your content